<DOC>
	<DOCNO>NCT02535767</DOCNO>
	<brief_summary>The purpose study determine high tolerable dose primaquine within 0.75 mg/kg . A tolerable dose define one : - Two few participant ( &lt; 30 % ) experience hemolysis ; - No participant experience drug-related serious adverse event ; - No participant require blood transfusion .</brief_summary>
	<brief_title>Determining Tolerable Dose Primaquine G6PD-deficient Persons Without Malaria Mali</brief_title>
	<detailed_description>Purpose : The purpose study determine high tolerable dose primaquine within 0.75 mg/kg . A tolerable dose define one : - Two few participant ( &lt; 30 % ) experience hemolysis ; - No participant experience drug-related serious adverse event ; - No participant require blood transfusion . Design : - This open-label , phase 2 , dose-adjustment study . - The initial primaquine dose 0.40 mg/kg . Subsequent dose group select depend occurrence adverse event previous dose group . Once high tolerable dose G6PD-deficient ( G6PDd ) individual establish , control group G6PD normal malaria-free men enrol evaluated high tolerable dose primaquine . Study Population : - Malian men age 18-50 year without malaria infection . - The majority study participant G6PDd . Study Size : This study enroll 7 participant per dose group . If dose group test , study enroll approximately 28 participant . Study visit duration : - Each participant follow 28 day . - Participants evaluate hemolysis adverse event Days 1-10 , 14 , 28 follow assign primaquine dose . Primary objective : To measure change hemoglobin among G6PD deficient west-African men follow single low-dose primaquine exceed 0.75 mg/kg . Secondary objective : 1 . To measure occurrence adverse event , grade severity , primaquine dose among G6PD deficient men 2 . To measure occurrence marker acute hemolytic anemia ( AHA ) , primaquine dose among G6PD deficient men . AHA marker include : - Absolute fractional change hemoglobin day 7 vs. baseline - Urine color - Reticulocyte count - Bilirubin ( total direct ) - Methemoglobin concentration - Development physical sign symptom hemolytic anemia 3 . To compare change hemoglobin , frequency severity adverse event , occurrence marker AHA G6PD deficient non-deficient participant receive high tolerable primaquine dose 4 . To measure G6PD enzyme activity ( semiquantitative testing , U / gHb ) 5 . To measure pharmacokinetics primaquine , carboxyprimaquine , metabolites accord plasma concentration . 6 . To genotype participant blood sample cytochrome P450 2D6 ( CYP2D6 ) single nucleotide polymorphism ( SNPs ) , determine potential hemolysis G6PDd individual affect CYP2D6 metabolizer status ( e.g . weak metabolizers and/or intermediate metabolizers )</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<criteria>Males age 18 50 ( inclusive ) Ability swallow oral medication Informed consent Willing able participate study 28 day For G6PDd participant : G6PDd define Carestart 3 rapid diagnostic test The OSMMR2000 G6PD qualitative test For G6PDn participant : G6PDn define Carestart 3 rapid diagnostic test The OSMMR2000 G6PD qualitative test Moderate severe anemia ( Hb &lt; 10 g/dL ) Malaria infection blood smear Individuals know positive HIV test Individuals know positive hepatitis B test . Known allergy study drug Current use medication ( tuberculosis , HIV , drug hemolytic potential G6PDd individual include sulphonamides , dapsone , nitrofurantoin , nalidixic acid , ciprofloxacin , methylene blue , toluidine blue , phenazopyridine , cotrimoxazole ) The individual unwilling abstain ingestion grapefruitcontaining product 72 hour prior start dose study complete Use antimalarial within 2 week contact study team report patient History blood transfusion bleed &gt; 500 mLs within last 3 month , report patient Reported history high alcohol intake ( &gt; 14 unit per week , unit equivalent 10 g alcohol ( 1 glass wine 1 bottle beer one shot distil spirit ) , within 6 month study report patient Reported use illicit drug ( marijuana , heroin , cocaine , methamphetamine ) dependence within 6 month study , report patient Participants vomit within 1 hour administration primaquine ( remove analysis count towards total sample size , though follow enrolled individual ) Already enrol study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Primaquine</keyword>
</DOC>